FITC Annexin V Apoptosis Detection Kit with PI

Pricing & Availability
Regulatory Status
RUO
Other Names
Annexin A5 Apoptosis Detection Kit
Ave. Rating
Submit a Review
Product Citations
publications
FITC_Annexin-V_kit_052318
Human T leukemia cell line Jurkat, treated (left) or non-treated (right) with BioLegend’s anti-human CD95 (EOS9.1) mAb (Cat. No. 305704) for 4 hours at 37°C, then stained with Annexin V- FITC for 15 minutes at 37°C in Annexin V Binding buffer. Propidium Iodide (PI) (cat. 421301 at 0.03 µg/Test) was added 5 minutes prior to running tubes.
  • FITC_Annexin-V_kit_052318
    Human T leukemia cell line Jurkat, treated (left) or non-treated (right) with BioLegend’s anti-human CD95 (EOS9.1) mAb (Cat. No. 305704) for 4 hours at 37°C, then stained with Annexin V- FITC for 15 minutes at 37°C in Annexin V Binding buffer. Propidium Iodide (PI) (cat. 421301 at 0.03 µg/Test) was added 5 minutes prior to running tubes.
See FITC spectral data
Cat # Size Price Quantity Check Availability Save
640914 100 tests 203€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

BioLegend's FITC Annexin V Apoptosis Detection Kit with PI has been specifically designed for the identification of apoptotic and necrotic cells.

Annexin V (or Annexin A5) is a member of the annexin family of intracellular proteins that binds to phosphatidylserine (PS) in a calcium-dependent manner. PS is normally only found on the intracellular leaflet of the plasma membrane in healthy cells, but during early apoptosis, membrane asymmetry is lost and PS translocates to the external leaflet. Fluorochrome-labeled Annexin V can then be used to specifically target and identify apoptotic cells. Annexin V Binding Buffer is recommended for use with Annexin V staining. Annexin V binding alone cannot differentiate between apoptotic and necrotic cells. To help distinguish between the necrotic and apoptotic cells we recommend use of our Propidium Iodide Solution (PI). Early apoptotic cells will exclude PI, while late stage apoptotic cells and necrotic cells will stain positively, due to the passage of these dyes into the nucleus where they bind to DNA.

Propidium iodide is a fluorescent dye that binds to DNA. When excited by 488 nm laser light, it can be detected with in the PE/Texas Red® channel with a bandpass filter 610/10. It is commonly used in evaluation of cell viability or DNA content in cell cycle analysis by flow cytometry.
 

Product Details
Technical data sheet

Product Details

Verified Reactivity
Human, Mouse, Rat
Reported Reactivity
Other Species
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
Store between 2°C and 8°C. Do not freeze.

Caution: Propidium Iodide Solution is toxigenic and mutagenic; handle with care.
Application

FC - Quality tested

Recommended Usage

Staining Procedure:
1. Wash cells twice with cold BioLegend's Cell Staining Buffer, and then resuspend cells in Annexin V Binding Buffer at a concentration of 0.25-1.0 x 107 cells/mL.
2. Transfer 100 µL of cell suspension in a 5 mL test tube.
3. Add 5 µL of FITC Annexin V.
4. Add 10 µL of Propidium Iodide Solution.
5. Gently vortex the cells and incubate for 15 min at room temperature (25°C) in the dark.
6. Add 400 µL of Annexin V Binding Buffer to each tube. Analyze by flow cytometry with proper machine settings.

Application Notes

Materials Provided:
0.5 ml of FITC Annexin V
1 ml of Propidium Iodide Solution
50 ml of Annexin V Binding Buffer

Materials Not Included:
Cell Staining Buffer (Cat. No. 420201)

For a better experience detecting apoptosis, we now recommend Apotracker™. Cell staining with Apotracker™ is Calcium independent. Thus, no special buffers are required, and the protocol can be shortened for single-step co-staining with other reagents.

Application References

(PubMed link indicates BioLegend citation)
  1. Ranhanathan P, et al. 2013. J AM Soc Nephrol. PubMed
  2. Yu J, et al. 2014. PloS One. 9:114650. PubMed
  3. Wang Y, et al. 2014. Biochem Biophys Res Commun. 456:656. PubMed
  4. Jaishy B, et al. 2015. J Lipid Res. 56:546. PubMed
Product Citations
  1. Ho J, et al. 2016. PLoS Biol. 14:e2000117. PubMed
  2. Markowicz-Piasecka M, et al. 2020. Apoptosis. 25:426. PubMed
  3. Lyu X, et al. 2019. Oncol Rep. 41:3137. PubMed
  4. Su T, et al. 2021. Metabolites. 11:. PubMed
  5. Tiu GC, et al. 2021. Dev Cell. 56:2089. PubMed
  6. Zelenka T, et al. 2022. Nat Commun. 13:6954. PubMed
  7. Li MM, et al. 2018. Int J Infect Dis. 70:72. PubMed
  8. Fang H, et al. 2022. Exp Ther Med. 24:440. PubMed
  9. Chen J, et al. 2021. Antioxidants (Basel). 10:. PubMed
  10. Shimonosono M, et al. 2021. Biomolecules. 11:. PubMed
  11. Wang C, et al. 2021. Clin Transl Med. 11:e522. PubMed
  12. Yuan L, et al. 2015. Endocr Relat Cancer. 22: 577 - 591. PubMed
  13. Belo H, et al. 2015. PLoS One. 10: e0139740. PubMed
  14. Morita K, et al. 2020. Cell. 702:181. PubMed
  15. Yang J, et al. 2021. Oncoimmunology. 1875638:10. PubMed
  16. Guo Q, et al. 2018. Front Immunol. 9:1197. PubMed
  17. Soonthornchai W, et al. 2019. Asian Pac J Allergy Immunol. N/A. PubMed
  18. Son Y, et al. 2020. Mol Metab. 39:101005. PubMed
  19. Xie T, et al. 2021. Ann Transl Med. 9:1249. PubMed
  20. Kocak P, et al. 2021. Macromol Biosci. 21:e2000287. PubMed
  21. Li D, et al. 2022. Sci Adv. 8:eabm0478. PubMed
  22. Choromanska A, et al. 2020. Biomed Rep. 13:32. PubMed
  23. Mahmoud A, et al. 2016. Int J Toxicol. 35: 429 - 437. PubMed
  24. Liu J, et al. 2015. Biochem Biophys Res Commun. 463: Pags 262-267. PubMed
  25. Wang Y, et al. 2014. Biochem Biophys Res Commun. 456:656. PubMed
  26. Neumann CKA, et al. 2020. Mol Metab. 34:136. PubMed
  27. Ali DM, et al. 2019. Cell Death Discov. 5:128. PubMed
  28. Yao J, et al. 2018. Onco Targets Ther. 11:3793. PubMed
  29. Chang T, et al. 2016. Sci Rep. 6:23403. PubMed
  30. Shao M, et al. 2018. Evid Based Complement Alternat Med. 2018:6049498. PubMed
  31. Coelho CC, et al. 2019. Sci Rep. 9:11050. PubMed
  32. Orgaz JL, et al. 2020. Cancer Cell. 37:85. PubMed
  33. Vashist A, et al. 2022. Asian Pac J Cancer Prev. 23:3629. PubMed
  34. Korencak M, et al. 2019. JCI Insight. 4. PubMed
  35. Zhang W, et al. 2021. J Clin Invest. 131:. PubMed
  36. Kang DY, et al. 2022. J Oncol. 2022:6737248. PubMed
  37. Saboor-Maleki S, et al. 2016. Technol Cancer Res Treat. 10.1177/1533034616650119. PubMed
  38. Tatsuno K, et al. 2019. Cell Death Dis. 10:578. PubMed
  39. Ouyang J, et al. 2019. J Surg Res. 233:221. PubMed
  40. Xiao Y, et al. 2020. Nucleic Acids Res. 48:11113. PubMed
  41. Shen L, et al. 2021. Cell Death Discov. 7:392. PubMed
  42. Lian W, et al. 2022. J Immunol Res. 2022:3129765. PubMed
  43. Wu J, et al. 2020. Immunity. 53:115. PubMed
  44. Sareddy G, et al. 2016. Sci Rep. 6: 24185. PubMed
  45. Xie L, et al. 2020. Front Oncol. 1.354166667. PubMed
  46. Fei X, et al. 2019. Cancer Manag Res. 11:4781. PubMed
  47. Balachandran C, et al. 2017. Biomed Pharmacother. 10.1016/j.biopha.2017.06.096. PubMed
  48. Kiss E, et al. 2021. Int J Mol Sci. 22:. PubMed
  49. Cao W, et al. 2016. Nat Commun. 7:11687. PubMed
  50. Finetti F, et al. 2020. Cell Death Differ. 27:310. PubMed
  51. Xing W, et al. 2020. J Recept Signal Transduct Res. 1:. PubMed
  52. Virumbrales–Muñ oz M, et al. 2019. Sci Rep. 9:6199. PubMed
  53. Allur Subramaniyan S, et al. 2018. Cell Commun Adhes. 24:19. PubMed
  54. Chen J, et al. 2021. J Oncol. 2021:5572402. PubMed
  55. Liu R, et al. 2021. Oncol Lett. 21:06. PubMed
  56. Perez E, et al. 2020. J Immunol. 205:2489. PubMed
  57. Callender LA, et al. 2021. Nat Commun. 12:3379. PubMed
  58. Blue E, et al. 2015. Diabetes. 64: 2664 - 2675. PubMed
  59. Kongkavitoon P, et al. 2016. PLoS One. 11: 0146696. PubMed
  60. Coden ME, et al. 2020. J Immunol. 204:438. PubMed
  61. Sohrabi Y, et al. 2019. Front Immunol. 9:3155. PubMed
  62. Changizi V, et al. 2021. Iran J Med Sci. 46:291. PubMed
  63. Zhang N, et al. 2021. Atherosclerosis. 334:39. PubMed
  64. Hu K, et al. 2020. Nat Commun. 2778:11. PubMed
  65. Jaishy B, et al. 2015. J Lipid Res. 56:546. PubMed
  66. Shin JJ, et al. 2020. Cell Rep. 32:108093. PubMed
  67. Soonthornchai W, et al. 2021. Sci Rep. 11:14186. PubMed
  68. Still C 2nd, et al. 2021. Cell Reports Medicine. 2(7):100343. PubMed
  69. Tailor D, et al. 2020. Br J Cancer. . PubMed
  70. Ryva B, et al. 2019. Front Oncol. 9:100. PubMed
  71. Flegkas A, et al. 2019. Medicines (Basel). 6:1. PubMed
  72. Wu A, et al. 2020. Cell Death Dis. 11:40. PubMed
  73. Patil M, et al. 2021. Circ Res. 129:1006. PubMed
  74. Abokyi S, et al. 2021. Int J Mol Sci. 22:. PubMed
  75. Huang S, et al. 2022. J Cancer. 13:2662. PubMed
  76. Merikhian P, et al. 2022. Mol Oncol. 16:485. PubMed
  77. Zhou Y, et al. 2021. NPJ Regen Med. 6:34. PubMed
  78. Ma H, et al. 2015. Sci Rep. 5: 15121. PubMed
  79. Kan L, et al. 2015. PLoS One. 10: 0144513. PubMed
  80. Wang YL, et al. 2021. Environ Health Perspect. 129:57003. PubMed
  81. Zhou L, et al. 2021. Front Oncol. 11:668617. PubMed
  82. Dudek M, et al. 2021. Nature. 592:444. PubMed
  83. Rodriguez E, et al. 2021. Cancers (Basel). 13:. PubMed
  84. Zhou Q, et al. 2020. J Invest Dermatol. . PubMed
  85. Chou ST, et al. 2020. Chin Med. 0.678472222. PubMed
  86. Weiss R, et al. 2015. Innate Immunity. 21: 813 - 826. PubMed
  87. Yu J, et al. 2014. PLoS One. 9:114650. PubMed
  88. Viereckl MJ, et al. 2022. Biomolecules. 12:. PubMed
  89. Roupakia E, et al. 2021. Cancers (Basel). 13:. PubMed
  90. Pires D, et al. 2021. Front Immunol. 12:647728. PubMed
  91. Lonardi S, et al. 2020. Cancer Immunol Res. 829:8. PubMed
  92. Cho S, et al. 2019. Transl Oncol. 0.820138889. PubMed
  93. Wang JS, et al. 2021. Nat Commun. 12:6271. PubMed
  94. Li XR, et al. 2020. Neoplasma. 67:982. PubMed
  95. Zakharova I, et al. 2022. Front Bioeng Biotechnol. 10:772981. PubMed
  96. Yang Y, et al. 2022. Int J Mol Sci. 23:. PubMed
  97. Choromanska A, et al. 2020. Pharmaceutics. 12:00. PubMed
  98. Levy G, et al. 2015. PLoS One. 10: 0136070. PubMed
  99. Zamani K, et al. 2021. BMC Biotechnol. 21:68. PubMed
  100. Biadglegne F, et al. 2021. Mol Med Rep. 24:. PubMed
  101. Li C, et al. 2018. Cell Physiol Biochem. 45:366. PubMed
  102. Wang X, et al. 2020. Onco Targets Ther. 13:1691. PubMed
  103. Wang N, et al. 2020. Front Immunol. 1.765972222. PubMed
  104. Zhong X, et al. 2021. Oncol Lett. 245:21. PubMed
  105. Wang W, et al. 2020. Cancer Cell Int. 1.06875. PubMed
  106. Lin B, et al. 2020. Mol Med Rep. 21:2171. PubMed
  107. Zheng M, et al. 2019. Proc Natl Acad Sci U S A. 116:12422. PubMed
  108. Lauko A, et al. 2022. Cell Rep. 40:111348. PubMed

Antigen Details

Biology Area
Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Neuroscience
Gene ID
308 View all products for this Gene ID

Related FAQs

How is your Annexin made and what sequence does it cover?

It is made in E. coli, covering human aa Met1-Asp320.

How does pH and staining temperature affect Annexin V-Phosphatidylserine binding?

Annexin-Phosphatidylserine binding is lost below pH 5.2 and with prolonged incubation over a temperature of 42°C.

Why do I need to use Annexin V Binding Buffer?

Annexin V binding requires the presence of calcium in the solution.  So, we provide Annexin V Binding Buffer (cat # 422201), which is optimized for the best performance of Annexin V staining.

Can I use RPMI during Annexin V staining?

It is best to follow protocol as described on the product data sheet. Moreover, RPMI 1640 has a relatively high concentration of phosphate and low calcium ion concentration, which negatively impacts Annexin binding to its target phosphatidylserine (PS). Measurement of cell death by using Annexin V may also be significantly affected by time of incubation on ice, calcium concentration, and type of medium.

Can I freeze Annexin V conjugates?

It should not be frozen as it will lead to loss of biological activity due to dimerization.

Is Annexin V suitable for conjugation with the Maxpar® kit for CyTOF®?

Maxpar® Labeling kits require the protein to be partially reduced, so the metal chelate can be introduced through an SH group in the hinge region of the reduced antibody. Human Annexin V contains only one Cysteine which was reported to be chemically inactive. Thus, the Maxpar® labeling protocol would not work with Annexin V, unless a free –SH group can be introduced to Annexin V.  For more information regarding SH-mediated conjugation of Annexin V please consult published papers such as this one.

Go To Top Version: 4    Revision Date: 11.01.2023

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account